ClinicalTrials.gg
RecruitingNCT06362252Updated Oct 1, 2026

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

A Phase 1/2 interventional study of Ifinatamab deruxtecan and Atezolizumab in Extensive Stage-small Cell Lung Cancer, sponsored by Daiichi Sankyo. Recruiting at 58 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Daiichi Sankyo · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.
Updated Oct 1, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 629 studies in Small Cell Lung Carcinoma with a site in United States — 111 open to participants now, 182 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.

Planned enrollment
161st of 550
123 · median 55
Started
2024
with 17 others
Phase 1/2
113 of 629
32 open now
Primary completion
2027-07
later than 69 of 181 live
Registered
544th of 629
by date

Among the 629 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 161st largest by planned enrollment of the 550 interventional ones that give a count, is one of 18 that started in 2024, is one of 113 in phase 1/2, reaches primary completion later than 69 of the 181 other live ones, and was the 544th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

111 of the 629 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 629 studies in Small Cell Lung Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.

Read the detailed description

This study consists of two parts and two cohorts: Part A (Phase 1b; Safety Run-in) and Part B (Phase 2; Dose Optimization), Cohort 1 (I-DXd in maintenance) and Cohort 2 (I-DXd in induction + maintenance).

The primary objective of this study is to evaluate the safety and tolerability of I-DXd in combination with atezolizumab with or without carboplatin by assessing treatment-emergent adverse events (TEAEs) and other safety parameters which will inform optimal dose selection of I-DXd in the combination regimens (Dose Optimization Part B) of this study.

03

Conditions studied

  • Extensive Stage-small Cell Lung Cancer

Keywords

  • Extensive stage-small cell lung cancer (ES-SCLC)
  • Ifinatamab deruxtecan
  • I-DXd
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

A full list of inclusion/exclusion criteria are available in the protocol.

Inclusion criteria

Inclusion Criteria

Participants must meet all of the following criteria to be eligible for enrollment into the study:

  1. Sign and date the form (ICF), prior to the start of any study-specific qualification procedures.
  2. Adults ≥18 years or the minimum legal adult age (whichever is greater) at the time the ICF is signed.
  3. Has or cytologically confirmed diagnosis of ES-SCLC who will require (IL) therapy.
  4. For Cohort 1, participant has received 4 cycles of 1L induction therapy with carboplatin, etoposide, and atezolizumab for ES-SCLC with ongoing CR PR, CR, or SD per v1.1 assessed by the investigator.

    For Cohort 2, participant has received no prior treatment for ES-SCLC.

  5. For Cohort 2, participant has at least one according to RECIST v1.1 on computed tomography (CT) or magnetic resonance imaging (MRI) as assessed by the investigator.
  6. For Cohort 2, participant must have at least one lesion, amenable to core , and must consent to provide a pretreatment biopsy tissue sample and on-treatment biopsy.
  7. Has PS of ≤1 (assessed within 7 days before enrollment/randomization).
  8. Has adequate organ and bone marrow function within 7 days before the start of study treatment as specified in the study protocol.
  9. A female subject of (POCBP) is eligible to participate if the following conditions are met:

    1. Subject is not pregnant as confirmed by highly sensitive pregnancy test during Screening (within 3 days prior to enrollment/randomization)
    2. Subject does not breastfeed during the treatment period and for at least 8/5/6 months after last dose of I-DXd/atezolizumab/carboplatin, respectively.
    3. Subject agrees to adhere to a method that is highly effective and agrees not to donate eggs (ova, oocytes) to others or freeze/store eggs during the treatment period and for at least the time needed to eliminate each study drug after the last dose. The length of time required to continue contraception and avoid donating/freezing eggs after last dose for I-DXd/atezolizumab/carboplatin is 8/5/6 months, respectively. Preservation of eggs may be considered prior to first dose of study drug.
  10. A male subject capable of producing sperm is eligible to participate if he agrees to the following during the intervention period and for at least the time needed to eliminate each study drug. The length of time required to continue contraception and avoid donating sperm after last dose for I-DXd/atezolizumab/carboplatin is 6/5/6 months, respectively.

    1. Avoid donating sperm.
    2. Adhere to either of the contraception methods: true abstinence from penile-vaginal intercourse or uses a penile/external condom when having penile-vaginal intercourse with a non-subject of childbearing potential plus partner use of an additional contraceptive method.
  11. Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.

Exclusion criteria

Exclusion Criteria

Participants who meet any of the following criteria will be disqualified from entering the study:

  1. Has received prior treatment with orlotamab, enoblituzumab, or other B7-H3 targeted agents, including I-DXd.
  2. Prior discontinuation of an ADC that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities.
  3. Has received prior treatment with CD137 agonists or ICIs, including anti-cytotoxic T-cell lymphocyte-4, , and anti-PD-L1 therapeutic antibodies, except for atezolizumab for Cohort 1.
  4. Has inadequate before enrollment/randomization as specified in the study protocol.
  5. Has any of the following within the past 6 months: cerebrovascular accident, , or another arterial thromboembolic event.
  6. Has clinically active , spinal cord compression, or , defined as untreated and symptomatic, or requiring therapy with or anticonvulsants to control associated symptoms.
  7. Has corneal disease.
  8. Has uncontrolled or significant cardiovascular disease,.
  9. Has history of (non-infectious) ILD/pneumonitis that required corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at Screening.
  10. Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  11. Is on chronic steroid treatment (dose of 10 mg daily or more prednisone equivalent), except for low-dose inhaled steroids (for asthma/, topical steroids (for mild skin conditions), or intra-articular steroid injections.
  12. Has history of other than SCLC within the 5 years prior to randomization/enrollment, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, superficial gastrointestinal tract tumors, and non-muscle invasive bladder cancer curatively resected by endoscopic surgery.
  13. Has history of allogeneic bone marrow, stem cell, or solid organ transplant.
  14. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to V5.0, Grade ≤1 or baseline.
  15. Has history of to the drug substances, inactive ingredients in the drug product or severe hypersensitivity reactions to other monoclonal antibodies.
  16. Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection.
  17. Has active or uncontrolled (HIV) infection.
  18. Has active or uncontrolled or C virus (HBV or ) infection.
  19. Has history of disease.
  20. Has any evidence of severe or uncontrolled systemic diseases.
  21. Has received a within 30 days prior to the first dose of study drug.
  22. Is a female who is pregnant or breastfeeding or planning to become pregnant.
  23. Has prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the participant; alter the absorption, distribution, metabolism, or excretion of the study drug; or confound the assessment of study results.
  24. Has psychological, social, familial, or logistical factors that would prevent regular follow-up
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
123 participants (estimated)

Study arms

  • Experimental
    Cohort 1, Part A: Maintenance Only (I-DXd 12 mg/kg)

    Part A (Safety Run-in): Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W. A 5-day surveillance period between each of the first 3 participants (up to a maximum of 9 participants) dosed is included as a safety measure.

    Drug: Ifinatamab deruxtecan · Drug: Atezolizumab

  • Experimental
    Cohort 2, Part A: Induction + Maintenance (I-DXd 8 mg/kg)

    Part A (Safety Run-in): Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 8 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

    Drug: Ifinatamab deruxtecan · Drug: Atezolizumab · Drug: Carboplatin

  • Experimental
    Cohort 2, Part A: Induction + Maintenance (I-DXd 12 mg/kg)

    Part A (Safety Run-in): Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

    Drug: Ifinatamab deruxtecan · Drug: Atezolizumab · Drug: Carboplatin

  • Experimental
    Cohort 1, Part B: Maintenance (I-DXd 8 mg/kg)

    Part B: Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only starting at Cycle 1 Day 1. Maintenance therapy consisting of I-DXd 8 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W

    Drug: Ifinatamab deruxtecan · Drug: Atezolizumab

  • Experimental
    Cohort 1, Part B: Maintenance (I-DXd 12 mg/kg)

    Part B: Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only starting at Cycle 1 Day 1. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

    Drug: Ifinatamab deruxtecan · Drug: Atezolizumab

  • Experimental
    Cohort 2, Part B: Induction + Maintenance (I-DXd 8 mg/kg)

    Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 8 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

    Drug: Ifinatamab deruxtecan · Drug: Atezolizumab · Drug: Carboplatin

  • Experimental
    Cohort 2, Part B: Induction + Maintenance (I-DXd 12 mg/kg)

    Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of IL I-DXd induction therapy (12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×minIV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

    Drug: Ifinatamab deruxtecan · Drug: Atezolizumab · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Dose-limiting Toxicities Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A)

    Time frame: Cycle 1 Day 1 up to Cycle 1 Day 21 (each cycle is 21 days)

  2. Overall Number of Participants With Treatment-emergent Adverse Events Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A and B)

    Time frame: Baseline up to 37 months

Secondary outcomes

  1. Progression-free Survival As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A and B)

    Progression-free survival is defined as the time from the enrollment/randomization date to the earlier of the dates of the first documentation of disease progression assessed by BICR and investigator per RECIST v1.1 or death due to any cause.

    Time frame: From start date of study drug to the earlier date of the first objective documentation of radiographic disease progression assessed by BICR and investigator per RECIST v1.1 or death due to any cause, whichever occurs first, up to approximately 37 months

  2. Objective Response Rate Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)

    Objective response rate (ORR) is defined as proportion of subjects who achieved a best overall response of confirmed complete response (CR) or confirmed partial response (PR) per BICR and investigator according to RECIST v1.1.

    Time frame: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months

  3. Duration of Response As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)

    Duration of response (DoR) is defined as the time from the date of the first documentation of objective response (confirmed complete response \[CR\] or confirmed partial response \[PR\]) to the date of the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. The DoR will be calculated for responding participants (confirmed PR or confirmed CR) only.

    Time frame: From the date of first documentation of confirmed response (CR or PR) to the first documentation of objective progression or to death due to any cause, whichever occurs first, up to approximately 37 months

  4. Disease Control Rate As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)

    Disease control rate is defined as the proportion of participants who have achieved a best overall response of confirmed CR, confirmed PR, or SD by BICR and investigator assessment per RECIST v1.1.

    Time frame: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months

  5. Clinical Benefit Rate as Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)

    Clinical benefit rate (CBR) is defined as the proportion of participants who achieved a best overall response of confirmed CR, confirmed PR, or SD lasting for at least 180 days.

    Time frame: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months

  6. Time to Response As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)

    Time to response (TTR) is defined as the time from the date of enrollment/randomization to the date of the first documentation of objective response (confirmed CR or confirmed PR) in responding subjects.

    Time frame: From the start date of study drug to the date of the first documentation of response (CR or PR) that is subsequently confirmed, up to approximately 37 months

  7. Best Percentage Change in the Sum of Diameters (SoD) of Measurable Tumors As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)

    The best percentage change in SoD is defined as the percentage change in the smallest SoD from all post-baseline tumor assessments, taking as reference the baseline SoD.

    Time frame: Baseline up to approximately 37 months

  8. Overall Survival Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A and B)

    Time from the date of enrollment/randomization to the date of death due to any cause.

    Time frame: From the start date of study drug to the date of death due to any cause, whichever occurs first, up to approximately 37 months

  9. Pharmacokinetic Parameter Maximum Serum Concentration of I-DXd

    Maximum serum concentration (Cmax) will be assessed using non-compartmental methods.

    Time frame: Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)

  10. Pharmacokinetic Parameter Time to Maximum Serum Concentration of I-DXd

    Time to maximum serum concentration (Tmax) will be assessed using non-compartmental methods.

    Time frame: Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)

  11. Pharmacokinetic Parameter Area Under the Concentration Curve of I-DXd

    Area under the concentration-time curve up to the last quantifiable time (AUClast) and Area under the concentration-time curve during dosing interval (AUCtau) will be assessed using non-compartmental methods.

    Time frame: Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)

  12. The Number of Participants Who Are Anti-Drug Antibody (ADA)-Positive At Any Time and Who Have A Treatment-emergent Anti-Drug Antibody

    The ADA prevalence, which is the percentage of participants who are ADA positive at any time point (baseline or postbaseline), as well as the ADA incidence, which is the proportion of participants having treatment-emergent ADA during the study period, will be reported.

    Time frame: Baseline up to approximately 37 months

07

Study locations

55 of 58 sites recruiting
  • University of Alabama -Birmingham
    Birmingham, Alabama 35233, United States
    Recruiting
    • Principal Investigator · Contact
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
    Recruiting
    • Principal Investigator · Contact
  • David Geffen School of Medicine
    Los Angeles, California 90095, United States
    Not yet recruiting
    • Principal Investigator · Contact
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92663, United States
    Recruiting
    • Principal Investigator · Contact
  • Mayo Clinic-Jacksonville
    Jacksonville, Florida 32224, United States
    Recruiting
    • Principal Investigator · Contact
  • Advent Health Orlando
    Orlando, Florida 32804, United States
    Recruiting
    • Principal Investigator · Contact
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
    Recruiting
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
    Chicago, Illinois 60611, United States
    Recruiting
    • Principal Investigator · Contact
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Regents of the University of Minnesota
    Minneapolis, Minnesota 55455, United States
    Recruiting
    • Principal Investigator · Contact
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Recruiting
    • Principal Investigator · Contact
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03766, United States
    Recruiting
    • Principal Investigator · Contact
  • Astera Cancer Care
    East Brunswick, New Jersey 08816, United States
    Recruiting
  • John Theurer Cancer Center At Hackensack Umc
    Hackensack, New Jersey 07601, United States
    Recruiting
    • Principal Investigator · Contact
  • New York University Cancer Center - Laura and Isaac Perlmutter Cancer Center At Nyu Langone
    Mineola, New York 11501, United States
    Recruiting
    • Principal Investigator · Contact
  • NYU Langone Hospital - Long Island
    Mineola, New York 11501, United States
    Recruiting
    • Principal Investigator · Contact
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
    Recruiting
    • Principal Investigator · Contact
  • Columbia University Hervert Irving Comprehensive Cancer Center
    New York, New York 10032, United States
    Recruiting
    • Principal Investigator · Contact
  • Montefiore Medical Center
    New York, New York 10461, United States
    Recruiting
  • Lancaster General Hospital - Ann B Barshinger Cancer Institute
    Lancaster, Pennsylvania 17601, United States
    Recruiting
  • University of Pennsylvania, Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Thomas Jefferson University Hospital - Central
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
    • Principal Investigator · Contact
  • Scri Oncology Partners
    Nashville, Tennessee 37203, United States
    Recruiting
    • Principal Investigator · Contact
  • Next Virginia
    Fairfax, Virginia 22031, United States
    Recruiting
    • Principal Investigator · Contact
  • Northwest Cancer Specialists, P.C.-Vancouver
    Vancouver, Washington 98684, United States
    Recruiting
    • Principal Investigator · Contact
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Principal Investigator · Contact
  • Hopital Albert Calmette - Chu Lille
    Lille, 59037, France
    Recruiting
    • Principal Investigator · Contact
  • Centre Léon Bérard
    Lyon, 69008, France
    Recruiting
    • Principal Investigator · Contact
  • Hôpital de la Timone
    Marseille, 13005, France
    Recruiting
    • Principal Investigator · Contact
  • Institut Curie - Site de Paris
    Paris, 75005, France
    Recruiting
    • Principal Investigator · Contact
  • Hopital Tenon
    Paris, 75020, France
    Recruiting
    • Principal Investigator · Contact
  • Chu Rennes - Hopital Pontchaillou
    Rennes, 35000, France
    Recruiting
    • Principal Investigator · Contact
  • CHU Nantes - Hôpital Guillaume et René Laënnec
    Saint-Herblain, 44805, France
    Recruiting
    • Principal Investigator · Contact
  • Hôpital Foch
    Suresnes, 92151, France
    Recruiting
    • Principal Investigator · Contact
  • Institut Gustave Roussy
    Villejuif, 94805, France
    Not yet recruiting
    • Principal Investigator · Contact
  • NHO Himeji Medical Center
    Himeji-shi, 670-8520, Japan
    Recruiting
  • Kansai Medical University Hospital
    Hirakata-shi, 573-1191, Japan
    Recruiting
    • Principal Investigator · Contact
  • National Cancer Center Hospital East
    Kashiwa, 277-8577, Japan
    Recruiting
    • Principal Investigator · Contact
  • The Cancer Institute Hospital of Jfcr
    Kōtoku, 135-8550, Japan
    Recruiting
    • Principal Investigator · Contact
  • Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc. Saiseikai Kumamoto Hospital
    Kumamoto, 861-4193, Japan
    Recruiting
    • Principal Investigator · Contact
  • Shizuoka Cancer Center
    Nagaizumi-cho, 411-8777, Japan
    Recruiting
    • Principal Investigator · Contact
  • Niigata Cancer Center Hospital
    Niigata, 951-8566, Japan
    Recruiting
    • Principal Investigator · Contact
  • Okayama University Hospital
    Okayama, 700-8558, Japan
    Recruiting
    • Principal Investigator · Contact
  • Kindai University Hospital
    Ōsaka-sayama, 589-8511, Japan
    Recruiting
    • Principal Investigator · Contact
  • Tokushima University Hospital
    Tokushima, 770-8503, Japan
    Recruiting
  • Fujita Health University Hospital
    Toyoake-shi, 470-1192, Japan
    Recruiting
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
    Recruiting
    • Principal Investigator · Contact
  • Hospital Universitari Vall D'Hebron
    Barcelona, 8035, Spain
    Recruiting
    • Principal Investigator · Contact
  • Ico Girona - Hospital Universitari de Girona Dr Josep Trueta
    Girona, 17007, Spain
    Recruiting
    • Principal Investigator · Contact
  • ICO l'Hospitalet - Hospital Duran i Reynals
    L'Hospitalet de Llobregat, 08908, Spain
    Recruiting
    • Principal Investigator · Contact
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain
    Recruiting
    • Principal Investigator · Contact
  • Hospital Universitario Ramon Y Cajal
    Madrid, 28034, Spain
    Recruiting
    • Principal Investigator · Contact
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
    Recruiting
    • Principal Investigator · Contact
  • Next Madrid
    Madrid, 28223, Spain
    Recruiting
    • Principal Investigator · Contact
  • Hospital Regional Universitario de Malaga
    Málaga, 29010, Spain
    Recruiting
    • Principal Investigator · Contact
  • Hospital Universitario Virgen Macarena
    Seville, 41009, Spain
    Recruiting
    • Principal Investigator · Contact
  • Hospital Universitario Virgen Del Rocio
    Seville, 41013, Spain
    Recruiting
    • Principal Investigator · Contact
  • Hospital Alvaro Cunqueiro
    Vigo, 36312, Spain
    Recruiting
    • Principal Investigator · Contact
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2027, 35 months after the start.

Of 71 industry-sponsored phase 1/2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 74. This study's planned 35 months is below that.

Counting every sponsor, half of 98 studies reached it within 54 months; a quarter within 44 and three quarters within 97.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Sep 2026 → Jul 2027 and completion Dec 2026 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2024
First posted
Apr 12, 2024
StartActual
Jul 22, 2024
Primary completionEst.
Jul 20, 2027was Sep 2026
CompletionEst.
Feb 20, 2028was Dec 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Jul 20, 2027
Oct 1, 2026
Study completion
Dec 30, 2026→Feb 20, 2028
Oct 1, 2026
Contact
Study contact's phone or email changed: d•••@daiichisankyo.co.jp→d•••@daiichisankyo.com. See the current contact
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Primary completion Sep 30, 2026→Jul 20, 2027
    Study completion Dec 30, 2026→Feb 20, 2028
    Contact Study contact's phone or email changed: d•••@daiichisankyo.co.jp→d•••@daiichisankyo.com. See the current contact
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06362252
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Apr 12, 2024
Start date
Jul 22, 2024
Primary completion
Jul 20, 2027 (estimated)
Completion
Feb 20, 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

(US) Daiichi Sankyo Contact for Clinical Trial Information
Contact
CTRinfo_us@daiichisankyo.com
9089926400
(Asia) Daiichi Sankyo Contact for Clinical Trial Information
Contact
dsclinicaltrial_jp@daiichisankyo.com
+81-3-6225-1111 (M-F 9-5 JST
Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ifinatamab deruxtecan

Start the discussion